Our thorough, end-to-end process – combined with our disciplined approach to development and integrated technology capabilities – enables pharmaceutical partners to advance and accelerate clinical and research programs aimed at personalizing care for cancer patients. From early biomarker hypothesis testing to global acceleration, we can partner with you at any stage of your drug development journey to help maximize your program’s probability of success.
From early or late stage development through global commercialization, we employ our world-class capabilities and deep expertise to build a solid framework for your diagnostic strategy and help bridge the gap to patient access at every step along the way.
